RibiTool
Financiado
Ribitol phosphate chemical tools to probe the biology of a unique mammalian car...
Cell-surface proteins are decorated with a variety of different carbohydrate structures that play central roles in mammalian biology. The complex nature of glycan structures and the pathways by which they are assembled make it a c...
Cell-surface proteins are decorated with a variety of different carbohydrate structures that play central roles in mammalian biology. The complex nature of glycan structures and the pathways by which they are assembled make it a challenging task to decipher their exact function in cells, knowledge that is essential if we are to understand how malfunctioning leads to disease. This proposal aims to deliver innovative approaches to probe a distinct pathway of glycosylation essential to mammalian biology and to use these strategies to provide novel insights into the mechanisms underlying normal cellular functioning and disease pathology. The work programme is built around a specific type of O-linked cell-surface glycan that carries two critical ribitol-phosphate (RboP) residues, unique carbohydrates that so far have not been identified in other mammalian glycoconjugates. Failure to correctly assemble this glycan causes a range of congenital muscular dystrophies known as α-dystroglycanopathies. Despite its importance in disease pathology, many aspects of RboP utilisation and functioning in mammalian cells are poorly understood. The proposed programme offers a powerful and original approach to address these key issues in cell biology by creating a set of novel chemical tools. These tools will enable the probing and manipulation of both RboP-carrying glycoconjugates as well as the enzymes responsible for installing RboP onto the glycans in a cellular context. Integration of these tools with fundamental 3-D structural information and studies in cellular models of α-dystroglycanopathy will offer the unprecedented opportunity to directly link genetic defects to molecular and cellular aspects of enzyme function and through to observed changes in glycosylation status. These pioneering strategies will impact our fundamental understanding of key processes in mammalian cells and will also enable the exploitation of this unique pathway for the design of therapeutic strategies.
ver más
Duración del proyecto: 67 meses
Fecha Inicio: 2019-12-06
Fecha Fin: 2025-07-31
Fecha Fin: 2025-07-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-12-06
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-STG:
ERC Starting Grant
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
1M€
Líder del proyecto
UNIVERSITY OF YORK
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
566.88K€ |
Participante